Ariful Islam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ariful Islam has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- A. H. M. Khurshid Alam
Department of Pharmacy, University of Rajshahi, Rajshahi-6205, Bangladesh
1 shared publication - Abdur Nur Tushar
Department of Pharmacy, Atish Dipankar University of Science and Technology, Uttara-1230, Bangladesh
1 shared publication - Farhad Hossain
Department of Pharmacy, University of Rajshahi, Rajshahi 6205, Bangladesh
1 shared publication - Farjana Sharmin
Department of Pharmacy, Khwaja Yunus Ali University, Sirajganj - 6751, Bangladesh
1 shared publication - Kazi Mazharul Islam
Department of Pharmacy, Atish Dipankar University of Science and Technology, Uttara-1230, Bangladesh
1 shared publication - Mamunur Rashid
Department of Pharmacy, Atish Dipankar University of Science and Technology, Uttara-1230, Bangladesh
1 shared publication
Latest Publications
- 1 January 2026
- Published by Maad Rayan Publishing Company in Journal of Herbmed Pharmacology
- Vol. 15 (1) , 27-35
Investigation of cardioprotective effects of Leea rubra Blume leaves on isoproterenol-induced left ventricular hypertrophy in mice
Introduction: Cardiac hypertrophy is a risk factor for many cardiovascular diseases (CVDs). Species of the genus Leea have traditional cardioprotective uses, but their direct effects on the heart remain unreported. This study evaluated the cardioprotective activities of a crude methanolic extract (CME) of L. rubra leaves (LRL) in isoproterenol-induced cardiac hypertrophic mice (IIHM) using atorvastatin as a reference treatment. Methods: IIHM (induced with isoproterenol, 5 mg/kg, 7 days, intraperitoneally) were treated with CME of LRL (40 mg/kg or 80 mg/kg, 28 days, orally) and compared with a standard treatment group (atorvastatin, 20 mg/kg, 28 days, orally) and a negative control group (IIHM, placebo). The cardioprotective and hepatoprotective effects of the extract were evaluated by analysing the changes in blood biochemical parameters, including lipid profile (total cholesterol [TC], triglyceride [TG], high-density lipoprotein [HDL], and low-density lipoprotein [LDL]), cardiac troponin I (CTnI), serum glutamic pyruvic transaminase (SGPT), and serum glutamic oxaloacetic transaminase (SGOT). Analysis was conducted using various commercial test kits. The left ventricular weight and body weight (LVW/BW) ratio was also recorded. Results: LRL significantly improved the lipid profile by lowering TC, TG, and LDL while increasing HDL levels (P<0.0001). Significant cardioprotective (reduced serum CTnI level and LVW/BW ratio (P<0.0001)) and hepatoprotective (reduced serum SGPT and SGOT levels (P<0.0001)) activities were observed in IIHM compared with the negative control group. Conclusion: The present study found antihyperlipidemic, cardioprotective, and hepatoprotective activity after LRL treatment in IIHM. Further investigation is required to identify the compounds and molecular mechanisms responsible for these effects.
- 1 January 2026
- Published by Maad Rayan Publishing Company in Journal of Herbmed Pharmacology
- Vol. 15 (1) , 27-35
Investigation of cardioprotective effects of Leea rubra Blume leaves on isoproterenol-induced left ventricular hypertrophy in mice
Introduction: Cardiac hypertrophy is a risk factor for many cardiovascular diseases (CVDs). Species of the genus Leea have traditional cardioprotective uses, but their direct effects on the heart remain unreported. This study evaluated the cardioprotective activities of a crude methanolic extract (CME) of L. rubra leaves (LRL) in isoproterenol-induced cardiac hypertrophic mice (IIHM) using atorvastatin as a reference treatment. Methods: IIHM (induced with isoproterenol, 5 mg/kg, 7 days, intraperitoneally) were treated with CME of LRL (40 mg/kg or 80 mg/kg, 28 days, orally) and compared with a standard treatment group (atorvastatin, 20 mg/kg, 28 days, orally) and a negative control group (IIHM, placebo). The cardioprotective and hepatoprotective effects of the extract were evaluated by analysing the changes in blood biochemical parameters, including lipid profile (total cholesterol [TC], triglyceride [TG], high-density lipoprotein [HDL], and low-density lipoprotein [LDL]), cardiac troponin I (CTnI), serum glutamic pyruvic transaminase (SGPT), and serum glutamic oxaloacetic transaminase (SGOT). Analysis was conducted using various commercial test kits. The left ventricular weight and body weight (LVW/BW) ratio was also recorded. Results: LRL significantly improved the lipid profile by lowering TC, TG, and LDL while increasing HDL levels (P<0.0001). Significant cardioprotective (reduced serum CTnI level and LVW/BW ratio (P<0.0001)) and hepatoprotective (reduced serum SGPT and SGOT levels (P<0.0001)) activities were observed in IIHM compared with the negative control group. Conclusion: The present study found antihyperlipidemic, cardioprotective, and hepatoprotective activity after LRL treatment in IIHM. Further investigation is required to identify the compounds and molecular mechanisms responsible for these effects.